AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
LymphomaAntineoplastic Combined Chemotherapy ProtocolsLymphoma, B-CellLymphoma, Non-HodgkinLymphoma, T-CellLymphoma, Large B-Cell, DiffuseLymphoma, FollicularChemotherapy, AdjuvantBurkitt LymphomaLymphoma, B-Cell, Marginal ZoneCyclophosphamideLymphoma, T-Cell, PeripheralCombined Modality TherapyAntineoplastic AgentsDoxorubicinLymphoma, Mantle-CellLymphoma, T-Cell, CutaneousTreatment OutcomeT-Lymphocyte SubsetsHodgkin DiseaseLymphoma, AIDS-RelatedLymphoma, Large-Cell, AnaplasticCisplatinFlow CytometryReceptors, Antigen, T-CellCD4-Positive T-LymphocytesPrognosisDisease-Free SurvivalAntibodies, MonoclonalPeripheral NervesEtoposideSurvival AnalysisB-LymphocytesNeoplasm StagingMice, Inbred BALB CMice, TransgenicSurvival RateInterferon-gammaT-Lymphocytes, RegulatoryAntigens, CDImmunologic MemoryLymph NodesInterleukin-2CD8-Positive T-LymphocytesNeoadjuvant TherapyTime FactorsBreast NeoplasmsMethotrexateDrug Administration ScheduleMice, Inbred C57BLClone CellsLung NeoplasmsThymus GlandAntibodies, Monoclonal, Murine-DerivedLymphoma, Large-Cell, ImmunoblasticSpleenMice, KnockoutCytokinesReceptors, Antigen, T-Cell, alpha-betaEpitopes, T-LymphocyteTransplantation, AutologousLymphocyte ActivationNeoplasmsBleomycinPeripheral Nervous System DiseasesImmunohistochemistryDendritic CellsApoptosisCell ProliferationCell Line, TumorVinblastineAdoptive TransferMolecular Sequence DataReceptors, Antigen, T-Cell, gamma-deltaNeoplasm Recurrence, LocalFollow-Up StudiesSignal TransductionCell DifferentiationLymphocyte CountCytotoxicity, ImmunologicCytarabineVincristineCarboplatinImmune TolerancePaclitaxelAntigens, CD20Peripheral Nervous SystemSalvage TherapyAntigens, Differentiation, T-LymphocyteDrug Resistance, NeoplasmIfosfamideAntigens, CD4Hematopoietic Stem Cell TransplantationT-Lymphocytes, CytotoxicLymphocytesInduction ChemotherapyJurkat CellsCell LineAntigens, CD45Forkhead Transcription Factors
HodgkinPTCLDose chemotherapyAnaplasticAngioimmunoblastic T-cell lType of non-Hodgkin'High-doseTransplantationLymphoblasticMultiple myelomaMalignant lymphomaStandard chemotherapyTumorsRemissionRadiationBrentuximab vedotinBlood stemDiffuseALCLCancersAllogeneicPrognosticMycosis fungoidesIncidence of leukaemia and lymphomaBurkittRegimensBoneStem cell transplantsPrimary cutaneousCombination ChemotherapyDLBCLRefractory diseaseRelapseCTCLEtoposideDiagnosisTypes of lymphomasQuality of life during chTreatmentLymphoproliferativeLeukemiaCutaneous lymphomasProliferationPreviously untreated patientsTumor cellsInduction chemotherapy
Hodgkin29
  • Most non-Hodgkin lymphomas (NHL) in children are fast growing, aggressive cancers. (dana-farber.org)
  • The most common non-Hodgkin lymphoma diagnoses in children are Burkitt lymphoma, diffuse large B-cell lymphoma, lymphoblastic lymphoma, and anaplastic large cell lymphoma. (dana-farber.org)
  • Children and teens with rare childhood non-Hodgkin lymphoma are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through the Childhood Lymphoma Program in our Childhood Hematologic Malignancy Center . (dana-farber.org)
  • Learn more about childhood non-Hodgkin lymphoma , including diagnosis and treatment . (dana-farber.org)
  • The patient's medical history showed grade IVB nodular sclerosing Hodgkin lymphoma, which had been diagnosed in 2001. (cdc.gov)
  • PCNSL is now known to be a form of extranodal, high-grade non-Hodgkin B-cell neoplasm, usually large cell or immunoblastic type. (medscape.com)
  • Childhood non-Hodgkin lymphoma treatment can include chemotherapy, radiation therapy, targeted therapy, and high-dose chemotherapy with stem cell transplant. (nih.gov)
  • Brentuximab vedotin injection is used alone or in combination with other chemotherapy medications to treat adult patients with certain types of Hodgkin lymphoma. (medlineplus.gov)
  • Brentuximab vedotin is used in combination with other chemotherapy in pediatric patients 2 years or older as first treatment for Hodgkin lymphoma. (medlineplus.gov)
  • It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. (news-medical.net)
  • A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports. (news-medical.net)
  • Collectively, CTCL is classified as a type of non-Hodgkin lymphoma (NHL). (medscape.com)
  • ABSTRACT In view of the widespread use of pesticides in Egypt and the increasing incidence of leukaemia and lymphoma we aimed to assess pesticide exposure and other selected variables as risk factors for lymphoproliferative disorders (leukaemia and non-Hodgkin lymphoma). (who.int)
  • The risk was significant for cases of non-Hodgkin lymphoma but not chronic lymphocytic leukaemia. (who.int)
  • Peripheral T-cell lymphomas (PTCL) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. (edu.au)
  • The abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for ADCETRIS in both early- and advanced stage settings of classical Hodgkin lymphoma (cHL), and in patients with other CD30-expressing lymphomas and other rare cancers. (businesswire.com)
  • The investigation of ADCETRIS as a single agent or in novel combinations with other agents demonstrates its continued potential to help people impacted by early- and advanced stage Hodgkin lymphoma," said Marjorie Green, M.D., Senior Vice President and Head of Late-Stage Development at Seagen. (businesswire.com)
  • Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial. (cancernetwork.com)
  • Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
  • The major types are Hodgkin lymphoma Non-Hodgkin lymphoma See table Comparison of Hodgkin. (msdmanuals.com)
  • Hodgkin Lymphoma Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
  • Non-Hodgkin lymphoma is not one disease but rather a category of lymphocyte cancers with a number of subgroups largely divided into aggressive and indolent types. (msdmanuals.com)
  • Non-Hodgkin lymphoma is the 2nd most common cancer in HIV-infected patients Non-Hodgkin lymphoma AIDS-defining cancers in patients infected with HIV are Kaposi sarcoma Lymphoma, Burkitt (or equivalent term) Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of central nervous system read more , and some AIDS patients present with lymphoma. (msdmanuals.com)
  • Indeed, patients with non-Hodgkin lymphoma should generally be screened for HIV and hepatitis viruses. (msdmanuals.com)
  • Also, patients with a first-degree relative with Hodgkin or non-Hodgkin lymphoma have an increased risk of non-Hodgkin lymphoma. (msdmanuals.com)
  • Among 41 cases of non-Hodgkin lymphoma, 12 (29.27%) benefited from the R-CHOP protocol and full response was observed in 46.34% of them. (bvsalud.org)
  • In our practice, hematologic neoplasms are mainly lymphoproliferative syndromes and the most common varieties are non-Burkitt non Hodgkin lymphoma, high grade lymphomas, chronic lymphocytic lymphoma and multiple myeloma. (bvsalud.org)
  • To avoid immunosuppression in chronic lymphocytic leukaemia (CLL), there is an association between pesti- these patients all cases were selected non-Hodgkin lymphoma (NHL), cide exposure and lymphoproliferative before initiation of chemotherapy. (who.int)
  • The Hodgkin lymphoma, Waldenström disorders or not. (who.int)
PTCL23
  • However, results with this therapy in peripheral T-cell lymphoma (PTCL) are not well defined. (cun.es)
  • Salvage treatment results with HDC/ASCT in PTCL are similar to those found in corresponding aggressive B-cell lymphomas. (cun.es)
  • Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), is a subtype of peripheral T-cell lymphoma. (wikipedia.org)
  • Peripheral T-cell lymphoma (PTCL) is defined as a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer cells (NK cells) (see figure for an overview of PTCL subtypes). (wikipedia.org)
  • PTCL is a type of non-Hodgkin's lymphoma (NHL). (wikipedia.org)
  • PTCL specifically affects T-cells rather than B-cells, and results when T-cells develop and grow abnormally. (wikipedia.org)
  • About 30% of PTCL-NOS cases exhibit malignant T cells that are infected with the Epstein-Barr virus (EBV). (wikipedia.org)
  • When associated with EBV, PTCL-NOS is classified as one of the Epstein-Barr virus-associated lymphoproliferative diseases (see Epstein-Barr virus-associated peripheral T cell lymphoma, not otherwise specified) but the relationship of EBV to the development and progression of Epstein-Barr virus-associated PTCL-NOS is unclear. (wikipedia.org)
  • Currently PTCL is treated similarly to B-cell lymphomas. (wikipedia.org)
  • However, in recent years, scientists have developed techniques to better recognize the different types of lymphomas, such as PTCL. (wikipedia.org)
  • It is now understood that PTCL behaves differently from B-cell lymphomas and therapies are being developed that specifically target these types of lymphoma. (wikipedia.org)
  • electronic version] Retrieved May 19, 2009, from http://www.lymphoma.org/atf/cf/%7B0363CDD6-51B5-427B-BE48-E6AF871ACEC9%7D/PTCL.PDF Archived April 20, 2009, at the Wayback Machine Stein H, Bonk A, Tolksdorf G, Lennert K, Rodt H, Gerdes J (August 1980). (wikipedia.org)
  • Cytologic findings of peripheral T-cell lymphoma (PTCL) with high epitheloid cell content (Lennert's lymphoma) in imprint smear. (wikipedia.org)
  • Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy. (news-medical.net)
  • PTCL patients have typically poorer outcomes compared with aggressive B-cell lymphomas. (edu.au)
  • Although anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine and prednisone remain the standard first-line treatment for most aggressive PTCL, there are important variations including incorporation of novel agents, use of radiotherapy and judicious consideration of stem cell transplantation. (edu.au)
  • Pralatrexate is used to treat a certain type of cancer (peripheral T-Cell lymphoma-PTCL). (imedix.com)
  • We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. (e-crt.org)
  • Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. (e-crt.org)
  • FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). (guidelinecentral.com)
  • WATERTOWN, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T-cell Lymphoma (CTCL) and R/R Peripheral T-cell Lymphoma (PTCL). (ozarksfirst.com)
  • We look forward to providing an update on the KT-333 Phase 1 clinical trial later this year, including initial evaluation of its antitumor activity in the target patient populations, and to working with the lymphoma community to rapidly advance this first-in-class heterobifunctional degrader in CTCL and PTCL in addition to exploring its potential in other cancers. (ozarksfirst.com)
  • In June at the International Conference on Malignant Lymphoma (ICML), with a data cutoff date of May 1, 2023, Kymera presented data on thirteen patients who received a mean of five doses across the first four dose levels (DL1-4) of the trial, including patients with solid tumors, CTCL and PTCL. (ozarksfirst.com)
Dose chemotherapy9
  • High-dose chemotherapy with autologous stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with aggressive B-cell lymphomas. (cun.es)
  • Radiation therapy has been used as part of the treatment for this lymphoma in adults but may not be necessary if high dose chemotherapy is used in the treatment plan. (dana-farber.org)
  • Thereafter, the patient received autologous peripheral blood stem cell transplantation with high-dose chemotherapy (combination of ifosphamide, carboplatin and etoposide) as pretreatment. (karger.com)
  • High dose chemotherapy treatment for lymphoma is followed by the infusion of patients' own bloodforming stem cells to restore the function of the bone marrow. (mitacs.ca)
  • High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard of care in different hematologic malignancies. (uni-koeln.de)
  • Miyazaki K, Masuya M, Yamaguchi M, Isaka S, Nakase K, Kobayashi T, Nakamura S, Shiku H: Angioimmunoblastic T-cell lymphoma occurring four months after autologous peripheral blood stem cell transplantation with high-dose chemotherapy for follicular lymphoma. (karger.com)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • Treatment options for refractory ALL may include high dose chemotherapy, targeted therapy, immunotherapy, clinical trials , or palliative care to manage symptoms and improve quality of life. (medicalnewstoday.com)
  • Stem cell transplantation is performed after high-dose chemotherapy (HDC) to restore a cancer patient's blood and immune cell production capacity. (bdbiosciences.com)
Anaplastic7
  • Anaplastic large cell lymphomas (ALCLs) are distinguished from other lymphomas by their anaplastic cytology and constant membrane expression of the CD30 antigen (an activation marker for B or T cells). (medscape.com)
  • This ulcerated nodule of localized primary cutaneous CD30+ anaplastic large cell lymphoma is relatively nonspecific in appearance. (medscape.com)
  • Anaplastic lymphoma kinase (ALK) protein may be detected in most cases (60-70%) of systemic ALCL by immunohistochemistry. (medscape.com)
  • Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas. (news-medical.net)
  • Ultimately, however, anaplastic large cell lymphoma (ALCL) was diagnosed. (cancernetwork.com)
  • Oncological causes were then investigated, and ultimately, anaplastic large cell lymphoma was diagnosed. (cancernetwork.com)
  • The differential diagnosis includes other cutaneous lymphomas, particularly the cutaneous nasal type T/natural killer-cell lymphoma, mycosis fungoides, precursor T-cell lymphoblastic lymphoma, nonspecific peripheral T-cell lymphoma, cutaneous anaplastic large cell lymphoma, and subcutaneous panniculitic T-cell lymphoma. (nih.gov)
Angioimmunoblastic T-cell l2
  • We present an unusual case of monomorphic T cell PTLD with features of angioimmunoblastic T cell lymphoma in an 8-year-old heart transplant patient, presenting with cranial nerve palsy. (karger.com)
  • de Leval L, Gisselbrecht C, Gaulard P: Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. (karger.com)
Type of non-Hodgkin'2
  • a type of non-Hodgkin's lymphoma) in adult patients. (medlineplus.gov)
  • Folotyn Vial is a prescription drug used in chemotherapy to treat peripheral T-cell lymphoma, a type of non-Hodgkin's lymphoma that affects T-cells in the immune system. (imedix.com)
High-dose7
  • Treatment for primary central nervous system lymphoma requires high doses of chemotherapy that enter the central nervous system, such as high-dose methotrexate and high-dose cytarabine. (dana-farber.org)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • We have recently developed and tested a "second generation" EPOCH regimen (EPOCH II) to replace stem cell transplant for lymphomas requiring high-dose intensity, including poor prognosis untreated aggressive lymphomas, potentially curable relapsed lymphomas, and low-grade lymphomas. (cancer.gov)
  • This regimen is based on experimental/clinical observations that suggest infusion schedules may improve the therapeutic index of natural product-derived cytotoxics, and that high-dose alkylator therapy can overcome drug resistance in lymphoma. (cancer.gov)
  • High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. (ous-research.no)
Transplantation35
  • Estimate the failure-free survival rate in a cohort of relapsed Hodgkin's lymphoma and non-Hodgkin's lymphoma patients after retrieval therapy which includes peripheral blood stem cell transplantation (PBSCT) in patients who achieve a complete remission or partial remission. (knowcancer.com)
  • Treatment includes chemotherapy and often stem cell transplantation , either from the patient's own bone marrow (autologous) or sometimes from another person's bone marrow (allogeneic). (dana-farber.org)
  • Lymphoma was initially treated with chemotherapy, but relapse required autologous peripheral stem cell transplantation in July 2005. (cdc.gov)
  • Further relapses in 2006 and 2007 were treated with radiotherapy and chemotherapy, respectively, before the patient underwent an allogeneic peripheral stem cell transplantation in July 2008. (cdc.gov)
  • The goal of PBSC mobilization is to allow collection of sufficient CD34+ cells to proceed to transplantation. (uni-koeln.de)
  • Draoua HY, Tsao L, Mancini DM, Addonizio LJ, Bhagat G, Alobeid B: T-cell post-transplantation lymphoproliferative disorders after cardiac transplantation: a single institutional experience. (karger.com)
  • Yang F, Li Y, Braylan R, Hunger SP, Yang LJ: Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation. (karger.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • Journal of Stem Cell Research and Transplantation is an international, open access, peer reviewed, scholarly journal committed to publish articles in diversified fields of transplantations and applications of stem cell research. (slideshare.net)
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
  • The Journal of Stem Cell Research and Transplantation publishes latest scientific information, and is generously accessible across the world through internet to go halves the innovations of the researchers for intellectual advancement in this field. (slideshare.net)
  • 184 had no cardiac events after stem cell transplantation. (slideshare.net)
  • Discussion Stem cell transplantation is well and truly underway in South East Asia. (slideshare.net)
  • Stem cell transplantation, or bone marrow transplantation, is a treatment option for leukemia and other blood cancers. (medicalnewstoday.com)
  • The goal of stem cell transplantation is to replace diseased or damaged stem cells with healthy ones. (medicalnewstoday.com)
  • There are two main types of stem cell transplantation: autologous and allogeneic. (medicalnewstoday.com)
  • Autologous transplantation involves extracting a person's stem cells from the bone marrow or blood and freezing them before a person has chemotherapy or radiation therapy. (medicalnewstoday.com)
  • Allogeneic transplantation involves using stem cells from a donor - often a family member but sometimes a nonrelative. (medicalnewstoday.com)
  • Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma. (ucsf.edu)
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • The safety profile of venetoclax following allogeneic hematopoietic stem cell transplantation in patients with chronic lymphocytic leukemia appears to be comparable with other reports in clinical trials. (cancernetwork.com)
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • 30,000 patients with blood-related malignancies receive HDC, which, if the response is satisfactory, could subsequently be followed by hematopoietic stem cell transplantation (HSCT). (bdbiosciences.com)
  • 1 Improvements in transplantation techniques, including the wider use of cell selection, have contributed to a significant reduction in the morbidity and mortality associated with conventional transplantation. (bdbiosciences.com)
  • This pharmacologically induced egress of HSCs into peripheral blood, called mobilization, is utilized as the preferred strategy for generating HSCs for transplantation. (bdbiosciences.com)
  • 3 Autologous stem cell transplantation almost exclusively uses peripheral blood, while for allogeneic SCT, T-lymphocytes in the peripheral blood could pose some danger. (bdbiosciences.com)
  • The number of viable CD45+/CD34+ cells will determine the quality of the harvested specimen for transplantation. (bdbiosciences.com)
  • An accurate measurement of CD34 is critical for dose requirement protocols in stem cell transplantation. (bdbiosciences.com)
  • With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)
Lymphoblastic1
  • These malignancies are further characterized by the maturity and differentiation of the individual cell types and are divided into acute leukemias such as acute myeloid leukemia and acute lymphoblastic leukemia and chronic leukemias such as chronic myeloid leukemia and chronic lymphocytic leukemia. (medscape.com)
Multiple myeloma2
  • At the time of writing, bisphosphonates such as pamidronate and zolendronate, administered intravenously, are not typically used for management of lymphomas other than multiple myeloma. (jcda.ca)
  • HDC with transplant is now standard therapy in multiple myeloma, acute myeloid leukemia in first remission, and intermediate-grade non-Hodgkin's lymphoma. (bdbiosciences.com)
Malignant lymphoma1
  • He suffered recurrent pulmonary infections and succumbed to severe pneumonia with respiratory failure and pulmonary hypertension five years after the diagnosis of malignant lymphoma without evidence of recurrence of Hodgkin's disease. (hindawi.com)
Standard chemotherapy2
  • After standard chemotherapy failed, a liver biopsy was performed. (bvsalud.org)
  • In the context of prostate cancer, CTC molecular interrogation can enable longitudinal monitoring of key biological features during treatment with substantial clinical impact, as several biomarkers could predict tumor response to AR signaling inhibitors (abiraterone, enzalutamide) or standard chemotherapy (taxanes). (oaepublish.com)
Tumors9
  • These can occur in lymph nodes or in sites such as the gastrointestinal tract or the inner eyelids, where these tumors are referred to as mucosa-associated lymphoid tissue (MALT) lymphomas. (dana-farber.org)
  • PCNSL occurs at an incidence of 0.47 per 100,000 person-years, accounting for 4%-6% of extranodal lymphomas and 4% of newly diagnosed CNS tumors. (medscape.com)
  • Although the cells of origin are lymphocytes, PCNSL should be considered a brain tumor, because the therapeutic challenges resemble those of other brain tumors. (medscape.com)
  • The Phase 1 clinical trial of KT-333 is designed to evaluate the safety, tolerability, PK/PD and clinical activity of KT-333 dosed weekly in adult patients with relapsed and/or refractory lymphomas, leukemias and solid tumors. (ozarksfirst.com)
  • Since actively dividing cells are more sensitive to DNA damage and damage to cellular processes, chemotherapy is more effective in rapidly growing tumors. (dvm360.com)
  • According to Gompertzian growth kinetics, microscopic or small tumors are more likely to be rapidly growing and therefore more sensitive to chemotherapy. (dvm360.com)
  • Consequently, larger tumors are more likely to contain resistant tumor cells so we should use multiple effective drugs when the smallest about of disease is present to kill cells before resistance develops. (dvm360.com)
  • Consequently, chemotherapy is not as effective for bulky tumors as for microscopic disease. (dvm360.com)
  • Overview of Lymphoma Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. (msdmanuals.com)
Remission3
  • Relapsed or refractory disease represents a significant area of unmet need where chemotherapy intensification has limited efficacy and novel agents such as brentuximab vedotin and pralatrexate provide additional opportunities for attainment of remission and potential stem cell transplant. (edu.au)
  • Chemotherapy was initiated according to the protocol on remission induction of COAP (cyclophosphamide, vincristine, cytosine arabinoside and prednisone) for a six week period achieving total remission of the neoplasia. (vin.com)
  • Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. (lu.se)
Radiation10
  • It should be borne in mind that even in the absence of bisphosphonate use, chemotherapy combined with radiation treatment may cause necrosis of the jaw bones ( Fig. 1 ). (jcda.ca)
  • Treatments for leukemia include chemotherapy, radiation therapy, and stem cell transplants. (medicalnewstoday.com)
  • Chemotherapy, radiation therapy, targeted therapy, and stem cell or bone marrow transplant are common treatment options for leukemia. (medicalnewstoday.com)
  • Radiation therapy is a cancer treatment that uses high-energy radiation to destroy cancer cells. (medicalnewstoday.com)
  • Doctors can deliver radiation externally or internally, depending on the location of the cancer cells. (medicalnewstoday.com)
  • External radiation therapy involves delivering radiation to the cancer cells from outside the body using a linear accelerator. (medicalnewstoday.com)
  • Doctors transplant the donor's stem cells into the individual after chemotherapy or radiation therapy to replace their diseased or damaged stem cells. (medicalnewstoday.com)
  • It is essential to identify and initiate treatment early with chemotherapy and/or radiation therapy in all cases of nodal or visceral (including neural) involvement with lymphoma. (researchgate.net)
  • Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. (ous-research.no)
  • Decreased WBC count, leukopenia, is seen when supply is depleted by infection or treatment such as chemotherapy or radiation therapy, or when a hematopoietic stem cell abnormality does not allow normal growth/maturation within the bone marrow, such as myelodysplastic syndrome or leukemia. (medscape.com)
Brentuximab vedotin1
  • Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin. (ucsf.edu)
Blood stem4
  • OUTLINE: Patients receive 2 courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. (knowcancer.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • An important component is the study of immune modulation with IL-2 and peripheral blood stem cells (PBSC) on the generation of natural killer (NK) and lymphokine-activated killer cells (LAK), immune recovery, and eradication of microscopic disease posttherapy. (cancer.gov)
Diffuse5
ALCL4
  • ALCL was recognized in 1985, when tumor cells consistently demonstrated labeling by the monoclonal antibody Ki-1, a marker later shown to recognize the CD30 antigen. (medscape.com)
  • In 1988, ALCL was added as a distinct entity to the revised Kiel classification, and in 1994, it was included in the Revised European-American Lymphoma (REAL) classification. (medscape.com)
  • PC-ALCL is one of the primary cutaneous CD30 + T-cell lymphoproliferative disorders, a wide spectrum of disease, with lymphomatoid papulosis (LyP) at the benign end of the spectrum and PC-ALCL at the malignant end. (medscape.com)
  • Histologically, ALCL is characterized by sheets of large pleomorphic cells with abundant cytoplasm, horseshoe- or wreath-shaped nuclei, and multiple prominent nucleoli. (medscape.com)
Cancers4
  • Many of the agents used to treat recurrence of lymphoma or other cancers may also prevent wounds from healing and could interfere with osseointegration. (jcda.ca)
  • Chemotherapy is given in many different ways in the treatment of blood cancers. (leukaemia.org.nz)
  • For some types of blood cancers, chemotherapy may also be given intrathecally (into the spinal fluid) to prevent or treat any CNS disease. (leukaemia.org.nz)
  • 2. The most common cancers in the African Region are cancers of the cervix, breast, liver and prostate as well as Kaposi's sarcoma and non-Hodgkin's lymphoma. (who.int)
Allogeneic2
  • The Dana-Farber/Boston Children's Stem Cell Transplant Center offers autologous and allogeneic stem cell transplants and is active in researching new stem cell techniques. (dana-farber.org)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
Prognostic2
  • T-cell immunophenotype constitutes an unfavorable prognostic factor in aggressive non-Hodgkin's lymphomas. (cun.es)
  • Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. (lu.se)
Mycosis fungoides2
  • These diseases include mycosis fungoides and subcutaneous panniculitis-like T-cell lymphoma. (dana-farber.org)
  • Mycosis fungoides is the most common type, accounting for 60% of CTCLs and almost half of all primary cutaneous lymphomas. (medscape.com)
Incidence of leukaemia and lymphoma1
  • NK-cell lineages all of which are further incidence of leukaemia and lymphoma, and radiodiagnosis physician (for imag- classified as distinct entities including it is important to investigate whether ing). (who.int)
Burkitt1
  • the remaining 10% are T-cell, mantle cell, Burkitt, or indolent B-cell lymphomas. (medscape.com)
Regimens5
  • Anthracycline-containing chemotherapy regimens are commonly offered as the initial therapy. (wikipedia.org)
  • Patients received a median of 3(range: 2-6) prior chemotherapy regimens (exclusive of tositumomab/iodine-131tositumomab) before or after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • The mediannumber of chemotherapy regimens was 2 after tositumomab/iodine-131 tositumomaband prior to HSCT (range: 1-4). (cancernetwork.com)
  • Although significant strides have been made in the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL), major clinical advances have plateaued over despite the development of new chemotherapy regimens and strategies. (cancer.gov)
  • Diagnosis: Lymphoma Subjects with lymphoma must have progressed, had SD, or recurred after initial treatment regimens that include an anthracycline and an anti CD20 monoclonal antibody. (who.int)
Bone9
  • Some, such as dexamethasone, are relatively innocuous, whereas others, such as doxorubicin, are highly toxic to the bone marrow and rapidly dividing cells. (jcda.ca)
  • Because of their effects on the bone marrow, many chemotherapy agents cause a reduction in hemoglobin, platelets and white blood cells. (jcda.ca)
  • 2 HSCs are primarily found in bone marrow niches, but a small fraction of HSCs can also be found in the peripheral blood. (bdbiosciences.com)
  • 3 Following exogenous stimulation, such as chemotherapy or using growth factors such as granulocyte colony stimulating factor (G-CSF) and filgrastim, the number of HSCs in the peripheral blood increases, either becoming on par or even exceeding the number in the bone marrow. (bdbiosciences.com)
  • CD34, a transmembrane phosphoglycoprotein, is present on immature hematopoietic precursor cells and all hematopoietic colony-forming cells in bone marrow and blood, including unipotent and pluripotent progenitor cells. (bdbiosciences.com)
  • Flow cytometric enumeration of CD34+ HSCs and progenitor cells is an established method for the evaluation of bone marrow and stem cell grafts. (bdbiosciences.com)
  • Most lymphomas are nodal with variable involvement of the bone marrow and peripheral blood. (msdmanuals.com)
  • These are the malignant proliferations of abnormal clones of white blood cells within the bone marrow that are broadly categorized into lymphoid and myeloid neoplasms depending on the type of white cell proliferation. (medscape.com)
  • In general, immunohistochemistry will be used for lymph node biopsies, flow cytometry will be used for peripheral blood and bone marrow samples. (who.int)
Stem cell transplants1
Primary cutaneous2
  • Among the changes to CTCL classification were the addition of primary cutaneous acral CD8 + T-cell lymphoma as a new provisional entity. (medscape.com)
  • Also, the term "primary cutaneous CD4 + small/medium T-cell lymphoma" was changed to "primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder" because of its indolent clinical behavior and uncertain malignant potential. (medscape.com)
Combination Chemotherapy1
  • Chemotherapy is usually given as a combination of drugs (combination chemotherapy). (leukaemia.org.nz)
DLBCL3
  • [ 4 ] Clinical outcomes differ by histologic subtype with 5-year overall survival rates ranging from 30% in DLBCL to 79% in marginal zone lymphoma. (medscape.com)
  • The DLBCL type of primary central nervous system lymphoma (PCNSL) is composed of immunoblasts or centroblasts that have a predilection for blood vessels and thus demonstrate a typical angiocentric growth pattern. (medscape.com)
  • Initial lymphoma stage and number of previous treatment lines were identified as independent risk factors for EFS in DLBCL and HL patients. (smw.ch)
Refractory disease1
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
Relapse1
  • In addition, PD-1/PD-L1 interactions contribute to functional T-cell impairment, which fails to elicit minimal residual disease and may be related to leukemia relapse. (biomedcentral.com)
CTCL2
Etoposide1
  • To test this hypothesis, we developed and tested a mdr-1 reversal strategy in relapsed lymphomas using EPOCH (doxorubicin/vincristine/etoposide over 96 hrs days 1 to 4, prednisone daily days 1 to 5, cyclophosphamide bolus day 5) and dexverapamil. (cancer.gov)
Diagnosis4
  • An increase in the peripheral leukocyte count was noted 56 months after the diagnosis of MFH was made. (karger.com)
  • The alpha-fetoprotein was significantly increased and the diagnosis of a germ-cell tumor or neuroblastoma was suspected. (hindawi.com)
  • Upon conducting aspiratory cytology with a fine needle of the lymph nodes, the diagnosis was found to be of multicentric B-cell centroblastic lymphoma of the lymphocytes, polymorphic with a high degree of malignity, classified in the range of stage IV and as a sub-stage b in the worldwide system of the World Health Organization. (vin.com)
  • Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. (ucsf.edu)
Types of lymphomas1
  • ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of cHL that is expressed on the surface of several types of lymphomas. (businesswire.com)
Quality of life during ch2
  • Some supportive therapies, such as anti-nausea medications or growth factors to boost blood cell production, may help manage side effects and improve quality of life during chemotherapy. (medicalnewstoday.com)
  • These finding are particularly beneficial in the treatment of recurrent cancer when maintaining a good quality of life during chemotherapy is a priority and allows patients to have a natural, nutritional approach to preventing and managing chemotherapy adverse effects. (researchgate.net)
Treatment22
  • If this type of lymphoma is completely removed by surgery, no additional treatment may be necessary. (dana-farber.org)
  • Three critical pieces of information are needed before a decision is made about an implant: the type of chemotherapy drugs, the timing of the implant in relation to the last chemotherapy treatment, and the anticipated interval before the next chemotherapy treatment (if needed). (jcda.ca)
  • To be safe, the patient should be a minimum of 1 month and preferably 60 days past the final chemotherapy treatment. (jcda.ca)
  • The time following the most recent chemotherapy treatment is determined by the aggressiveness of the disease and treatment, whereas the time required for osseointegration is determined by the implant system, the location of the implant and the prosthetic treatment plan. (jcda.ca)
  • Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer. (news-medical.net)
  • An experimental treatment that combines intense chemotherapy with a radioactive isotope linked to synthesized neurotransmitter is being tested in newly diagnosed cases of high-risk neuroblastoma - a deadly, hard-to-cure childhood cancer. (news-medical.net)
  • Williams KM, Higman MA, Chen AR, Schwartz CL, Wharam M, Colombani P, Arceci RJ: Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. (karger.com)
  • Additional data from real-world settings further support the efficacy, safety and impact of ADCETRIS treatment in its approved indications for multiple types of lymphoma. (businesswire.com)
  • Government of LY294004 didn't more affect the Akt and PI3K phosphorylation that has been maximally suppressed by iPSCs at 5 107 cells/kg or even the equivalent level of iPSC CM. Meanwhile, such medicinal treatment also showed no effect on the details related to lung injury and neutrophil infiltration that have been maximally inhibited by iPSCs or iPSC CM in wild type recipients but not in Akt heterozygous knockout recipients. (pimpathway.com)
  • IL-2 treatment acutely increased the CD4 cells, all within the CD4RO subset, and increased NK and LAK cells. (cancer.gov)
  • Chemotherapy is the main form of treatment given for cancer. (leukaemia.org.nz)
  • In most cases you don't need to be admitted to hospital for chemotherapy, which is usually taken at home or given in the hospital's day treatment centre. (leukaemia.org.nz)
  • Chemotherapy can have a variety of side effects which are explained in more detail under 'Common side effects of treatment' . (leukaemia.org.nz)
  • Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC). (aihta.at)
  • Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy. (aihta.at)
  • Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC). (aihta.at)
  • 2. Clinical epidemiology - using data from the Swedish Lymphoma Registry to provide clinically useful real world data on treatment and prognosis, in many cases in collaboration with Nordic colleagues. (lu.se)
  • Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. (lu.se)
  • Living with lymphoma and having treatment can be a stressful time with many different challenges. (lymphoma.org.au)
  • However, this will depend on how you feel, what treatment you have and how whether you are having any symptoms from the lymphoma, or side-effects from treatment. (lymphoma.org.au)
  • Some people choose to continue their study while undergoing treatment, or caring for someone with lymphoma. (lymphoma.org.au)
  • Therefore, the recommended treatment which offers the best chance of survival to the patient is surgery, together with radiotherapy and chemotherapy 3,4,7,8 . (bvsalud.org)
Lymphoproliferative2
  • Morovic A, Jaffe ES, Raffeld M, Schrager JA: Metachronous EBV-associated B-cell and T-cell posttransplant lymphoproliferative disorders in a heart transplant recipient. (karger.com)
  • Lundell R, Elenitoba-Johnson KS, Lim MS: T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. (karger.com)
Leukemia7
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare and aggressive disease caused by human T-cell lymphotropic virus type 1 that predominantly affects Japanese and Caribbean populations. (oncotarget.com)
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare mature T-cell malignancy first described in Japan in 1977 [ 1 ]. (oncotarget.com)
  • Chemotherapy for leukemia can cause various side effects, depending on the specific drugs, the dosage, and the person. (medicalnewstoday.com)
  • Refractory ALL is a more challenging form of leukemia because the cancer cells have become resistant to standard treatments. (medicalnewstoday.com)
  • NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. (ucsf.edu)
  • Moreover, it has been shown that the PD-1 ligand (PD-L1) is highly expressed in leukemia cells. (biomedcentral.com)
  • Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (who.int)
Cutaneous lymphomas1
  • Cutaneous lymphomas are lymphomas that are only present in the skin. (dana-farber.org)
Proliferation4
  • The proliferation of names reflects initial uncertainty about the cell of origin. (medscape.com)
  • In addition, areas of hypoxia and decreased cell proliferation develop. (dvm360.com)
  • Such immune dysfunction may be due to a disorder in thymic output function (in particular in young patients), which results in a lower level of naive T-cells in the peripheral blood available for an immune response to the proliferation and abnormal expression of the T cell receptor (TCR) repertoire. (biomedcentral.com)
  • Cancer refers to a group of diseases characterized by abnormal cell proliferation with a tendency to invade adjacent tissues and produce metastases. (who.int)
Previously untreated patients1
  • Based on our results showing EPOCH to be effective and well tolerated, we began a phase II study of EPOCH in previously untreated patients with aggressive lymphomas. (cancer.gov)
Tumor cells5
  • In vitro , overexpression of the mdr-1 gene product, P-glycoprotein (Pgp), in tumor cells can confer high-level resistance to natural product-derived cytotoxics-anthracyclines, vinca alkaloids, epipodophyllotoxins, and taxanes. (cancer.gov)
  • The use of circulating tumor cells (CTCs) as a "liquid biopsy" to interrogate the molecular profile of single patients is extremely encouraging, as these cells originate from primary tumor and metastatic sites, providing a comprehensive fingerprint of a given tumor at any time during the course of the disease with a simple blood draw [ 7 ] . (oaepublish.com)
  • Each dose of chemotherapy kills a constant fraction of the tumor cells. (dvm360.com)
  • This hypothesis suggests that it is impossible for chemotherapy to eradicate all tumor cells and that we should treat with the highest tolerated doses (that are safe) given as frequently as is safe for the patient. (dvm360.com)
  • Moreover, increasing data have shown that peripheral T-cell tolerance is an essential property of the specific immune response to tumor cells. (biomedcentral.com)
Induction chemotherapy1